GlaxoSmithKline is trading at $50.75, up 4.20% pre-market on November 4, 2026, in a move that appears to align with a broader healthcare rally.
- XLV is up 1.55% pre-market; no clear company-specific news explains the rise.
- The latest quarterly report showed revenue growth, but vaccine sales fell, including Shingrix and Arexvy; that prior news does not explain today’s upward move.